Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Andrew M. Standeven is active.

Publication


Featured researches published by Andrew M. Standeven.


International Journal of Toxicology | 1989

Chromium(VI) Toxicity: Uptake, Reduction, and DNA Damage

Andrew M. Standeven; Karen E. Wetterhahn

Much recent data supports the “uptake-reduction” model explaining the carcinogenicity of chromium(VI) compounds and the lack of carcinogenicity of chromium(III) com pounds. Cr(VI) readily enters cells by diffusion through a nonspecific anion channel, whereas cells are relatively impermeable to Cr(III). Glutathione appears to facilitate Cr(VI) uptake by reducing Cr(VI) to Cr(III) after it enters the cell, presumably keeping intracellular Cr(VI) concentration low and allowing for further Cr(VI) uptake. Some other nonenzymatic factors, for example, ascorbate and riboflavin, as well as enzymes, such as cytochrome P-450, DT-diaphorase, and the mitochondrial electron transport chain complexes, are capable of reducing Cr(VI) in vitro, but their contribution in vivo is not clear. Cr(VI), once reduced intracellularly, produces various forms of DNA damage including DNA interstrand crosslinks, DNA-protein crosslinks, DNA strand breaks, and Cr-DNA adducts. The pathway of Cr(VI) metabolism in different tissues appears to influence the type of “reactive intermediates” produced, for example, Cr(V) and radical species, and thus the nature and extent of DNA damage. This DNA damage presumably accounts for observed functional changes in DNA replication and transcription which may be crucial to the carcinogenicity of chromium(VI) compounds.


Bioorganic & Medicinal Chemistry | 1999

Synthesis and biological activity of high-affinity retinoic acid receptor antagonists

Alan T. Johnson; Liming Wang; Andrew M. Standeven; Maria Escobar; Roshantha A. S. Chandraratna

This article reports the synthesis and biological activity of new high affinity retinioic acid receptor (RAR) antagonists. The effect of introducing heteroatoms in the bicyclic ring system of the potent dihydronaphthalene RAR antagonist 8, and the variation of the pendant aromatic group on the ability of these compounds to function as RAR antagonists is discussed. The use of binding, transcriptional, and in vivo assays revealed that the 2,2-dimethylthiochromene analogue 59, and the 2,2-dimethylchromene derivative 85, were the most effective in blocking retinoid agonist induced activity.


Toxicology Letters | 1997

Lack of involvement of retinoic acid receptor α in retinoid-induced skin irritation in hairless mice

Andrew M. Standeven; Min Teng; Roshantha A. S. Chandraratna

It has been proposed that RAR gamma, the major retinoic acid receptor (RAR) subtype in skin, mediates retinoid-induced skin irritation. However, RAR alpha is also found in skin, and its role in retinoid-induced skin irritation has not been tested. In this study, RAR subtype-specific agonists and antagonists were used to test the possible contribution of RAR alpha to retinoid-induced skin irritation. Female hairless mice were treated topically on the dorsal skin for 5 days with various retinoids over a 2-log dose range, and cutaneous toxicity was scored by semiquantitative visual observations of skin flaking and abrasions daily up to 3 days post-treatment. Three RAR alpha-selective agonists were > or = 100-fold less potent as skin irritants than the structurally-related RAR pan-agonist, TTNPB. Skin irritation potency decreased in the following order: TTNPB > > Am580 > AGN 193835 > > 193836 and correlated with RAR beta and/or RAR gamma binding affinity rather than RAR alpha binding affinity. TTNPB-induced skin irritation was blocked in a dose-dependent fashion by co-treatment with the RAR pan-antagonist AGN 193109 but was not blocked by co-treatment with the RAR alpha-specific antagonist AGN 194301. In contrast, skin irritation induced by the RAR alpha-selective agonist AGN 193835 was almost completely blocked by co-treatment with AGN 193644, an RAR beta/gamma-selective antagonist. These data demonstrate that RAR alpha is not significantly involved in mediating retinoid-induced skin irritation in mice and suggest that RAR alpha-selective agonists may have reduced mucocutaneous side effects relative to other retinoids.


Toxicology and Applied Pharmacology | 1991

Tissue-specific changes in glutathione and cysteine after buthionine sulfoximine treatment of rats and the potential for artifacts in thiol levels resulting from tissue preparation☆

Andrew M. Standeven; Karen E. Wetterhahn

L-Buthionine-S,R-sulfoximine (BSO), a potent inhibitor of gamma-glutamylcysteine synthetase, is commonly used as an experimental tool for the specific depletion of glutathione. Since cysteine is a key precursor for glutathione biosynthesis, we investigated the possibility that BSO might also affect the free cysteine pool in rat liver and kidney tissues in vivo. Male CD(SD)BR rats (150-200 g) were injected ip with various doses of BSO (0.25-4.0 mmol/kg), and glutathione and cysteine were measured in liver and kidney using HPLC with electrochemical detection and/or spectroscopic techniques. No hepatotoxicity or nephrotoxicity was observed at the highest BSO dose (4.0 mmol/kg) used. BSO caused the expected decreases of hepatic and renal glutathione at all doses, although glutathione depletion was more rapid, was achieved at a lower BSO dose, and was more sustained in kidney than in liver. Hepatic cysteine levels nearly doubled 20 min after BSO treatment (1.0 mmol/kg, ip), but were not significantly different from control at later time points. In contrast, renal cysteine was significantly depleted from 20 min to 25 hr postinjection with a time course closely paralleling that of renal glutathione depletion. These changes are discussed in the context of models for inter- and intraorgan transport of glutathione and cysteine. We also provide evidence that an artifact, most likely the gamma-glutamyltranspeptidase (GGT)-initiated breakdown of glutathione, leads to a rapid postmortem increase of cysteine levels in liver and particularly in kidney of rats. Simultaneous decreases in GSH levels can be demonstrated in kidney. This artifact needs to be minimized in toxicological studies of glutathione and cysteine in kidney and other GGT-rich organs, as the measured levels of these thiols may not reflect the true concentrations occurring in vivo.


Bioorganic & Medicinal Chemistry | 1999

A new class of RAR subtype selective retinoids: correlation of pharmacological effects with receptor activity.

Vidyasagar Vuligonda; Yuan Lin; Scott M. Thacher; Andrew M. Standeven; Devendra M. Kochar; Roshantha A. S. Chandraratna

The synthesis and biological activity of a series of structurally related retinoids with different RAR subtype selectivities are described. These retinoids bind to all three RAR subtypes but in functional transactivation assays, they show RARbeta or RARbeta,gamma selectivity with weak RARalpha activity. The subtype selectivity of these retinoids was found to correlate with their efficacy (ODC inhibition) and toxicity (topical irritation and teratogenicity) profiles. The degree of RARgamma transactivation activity correlates with their topical toxicity and teratogenicity as measured by the inhibition of chondrogenesis. Of the RARbeta selective retinoids reported here, retinoid 12 is the most promising, as it is completely devoid of two common retinoid related toxicities, namely topical irritation and teratogenesis.


Toxicology and Applied Pharmacology | 1990

Metabolism of the liver tumor promoter ethinyl estradiol by primary cultures of rat hepatocytes

Andrew M. Standeven; Yuenian E. Shi; J F Sinclair; Peter R. Sinclair; James D. Yager

Previously, we reported that relatively high micromolar concentrations of the liver tumor promoter 17 alpha-ethinyl estradiol (EE2) stimulated DNA synthesis and enhanced the DNA synthetic response to epidermal growth factor (EGF) in primary cultures of female rat hepatocytes [J.D. Yager, B.D Roebuck, T.L. Paluszcyk, and V.A. Memoli, Carcinogenesis 7, 2007-2014 (1986); Y.E. Shi and J.D. Yager, Cancer Res. 49, 3574-3580 (1989)]. In this study, our goal was to examine the metabolism of EE2 in cultured hepatocytes. After 4, 24, and 48 hr of culture, hepatocytes maintained their ability to convert up to 95% of a 4 nM concentration of [3H]EE2 to polar conjugates within 4 hr. EE2 at 2 microM was also 95% metabolized within 4 hr. HPLC analysis of the metabolites confirmed the rapid disappearance of [3H]EE2 and the formation of polar conjugates as detected by organic extraction. HPLC separation of hydrolyzed conjugates indicated that the major aglycone was the parent compound, EE2. In general, the metabolites differed both qualitatively and quantitatively from those reported in vivo in the rat. The rapid metabolism of EE2 by hepatocytes in culture may, at least in part, explain the high concentrations of EE2 required to stimulate DNA synthesis in cultured hepatocytes and to potentiate the response to EGF.


Bioorganic & Medicinal Chemistry Letters | 2001

Phenylcyclohexene and phenylcyclohexadiene substituted compounds having retinoid antagonist activity.

Richard L. Beard; Elliott S. Klein; Andrew M. Standeven; Maria Escobar; Roshantha A. S. Chandraratna

Retinoids are natural and synthetic analogues of the hormone retinoic acid. Systemic retinoid agonist therapy is usually associated with toxic side effects, such as mucocutaneous toxicity, which may be alleviated by the use of topical retinoid antagonists. We report the synthesis and biological activity of a new series of potent, RAR-specific antagonists substituted with phenylcyclohexene and phenylcyclohexadiene groups.


Archive | 1998

Synthesis and use of retinoid compounds having negative hormone and/or antagonist activities

Elliott S. Klein; Alan T. Johnson; Andrew M. Standeven; Richard L. Beard; Samuel J. Gillett; Tien T. Duong; Sunil Nagpal; Vidyasagar Vuligonda; Min Teng; Roshantha A. Chandraratna


Chemical Research in Toxicology | 1991

Is there a role for reactive oxygen species in the mechanism of chromium(VI) carcinogenesis

Andrew M. Standeven; Karen E. Wetterhahn


Carcinogenesis | 1992

Ascorbate is the principal reductant of chromium(VI) in rat lung ultrafiltrates and cytosols, and mediates chromium-DNA binding in vitro

Andrew M. Standeven; Karen E. Wetterhahn; Ryuichi Kato

Collaboration


Dive into the Andrew M. Standeven's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge